Patient Impact of Limited Provider PGX Knowledge | PGX For Pharmacists

According to the American Academy of Family Physicians, there are more than 50 Cytochrome P450 enzymes but there are just 6 of them that metabolize about 90% of the drugs. One of the most significant ones is the CYP2D6. In an article on healio written by Dr. Jai Patel, he talks about CYP2D6 metabolizing many of the SSRIs, SNRIs and TCAs that are the treatment options for depression. The clearance of TCA’s for example is 50-67% lowered in CYP2D6 poor metabolizers compared to normal. www.aafp.org/afp/2007/0801/p391.html  Pharmacogenetic testing may improve outcomes for patients with depression (healio.com) Kristine Ashcraft is a molecular biologist by training and is the former CEO and founder of YouScript which was recently acquired by Invitae. She has worked in pharmacogenomics space since 2000 and was recently named one of the 25 leading voices in precision medicine. Kristine has authored multiple publications on both the clinical and economic benefits of PGx testing. She serves on the Steering Committee of STRIPE which is the FDA collaborative community for PGx. She has been interviewed by numerous media including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at American Society of Human Genetics, and numerous precision medicine conferences and now speaking at one of the top 20 genomics podcast in the globe, PGx for Pharmacist Podcast.